and N1-propargylthymine 524 (164 mg, 1.00 mmol) in a mixture
of t-BuOH, H2O and pyridine (5 : 5 : 2 v/v, 12 mL) was added
sodium ascorbate (37 mg, 0.19 mmol) and CuSO4·5H2O (25 mg,
0.10 mmol) and the mixture was stirred at room temperature for 18
h. A second portion of N1-propargylthymine (164 mg, 1.00 mmol),
sodium ascorbate (37 mg, 0.19 mmol) and CuSO4·5H2O (25 mg,
0.10 mmol) was added and the mixture was stirred for another 3
h. Ethyl acetate (30 mL) was added and the mixture was washed
with water (30 mL). The aqueous phase was extracted with ethyl
acetate (3 ¥ 30 mL), and the combined organic phases were dried
(Na2SO4) and concentrated under reduced pressure. The residue
was purified by column chromatography (33–100% ethyl acetate
and 0.2% pyridine in petrolium ether) affording the product 13
nucleoside 14 (300 mg, 0.42 mmol) in anhydrous CH2Cl2 (5 mL)
was added N,N-diisopropylethylamine (350 mL, 2.00 mmol) and
2-cyanoethyl-N,N-diisopropylphosphoramidochloridite (300 mL,
1.35 mmol) and the mixture was stirred at room temperature
for 3 h. CH2Cl2 (30 ml) was added and the mixture was washed
with a saturated aqueous solution of NaHCO3 (30 mL). The
aqueous phase was extracted with CH2Cl2 (3 ¥ 30 mL) and the
combined organic phases were dried (Na2SO4) and concentrated
under reduced pressure. The residue was purified by column
chromatography (0-25% acetone and 0.2% pyridine in CH2Cl2)
to afford the product 15 (345 mg, 90%) as a colorless foam;
Rf 0.28 (25% acetone in CH2Cl2); 31P NMR (75 MHz, CDCl3)
d 152.07, 151.13; HRMS-ESI m/z 940.3541 [MNa]+: calcd
(C47H52N9O9PNa)+ 940.3518.
1
(500 mg, 80%) as a colorless foam; Rf 0.26 (ethyl acetate); H
NMR (300 MHz, CDCl3) d 9.60–9.30 (br s, 2H, NH), 7.72 (s, 1H,
H-6), 7.48–7.30 (m, 10H, H-5(triazole), Ar), 7.26 (s, 1H, H-6),
7.13–6.98 (m, 4H, Ar), 6.23 (dd, 1H, J = 4.8, 9.6 Hz, H-1¢), 4.95,
4.73 (AB, 2H, J = 15.0 Hz, CH2N), 4.15 (m, 1H, H-6¢), 3.74 (m, 1H,
H-5¢), 3.52 (dd, 1H, J = 3.9, 13.5 Hz, H-6¢) 3.25 (d, 1H, J = 4.5 Hz,
H-3¢), 3.19 (br s, 1H, H-4¢), 2.06 (s, 3H, CH3), 2.04–1.75 (m, 5H,
H-2¢, CH3), 0.66 (s, 9H, C(CH3)3), -0.22 (s, 3H, Si(CH3)2), -0.36 (s,
3H, Si(CH3)2); 13C NMR (75 MHz, CDCl3) d 164.3, 164.1 (C-4),
152.2, 152.0 (Ar), 150.9, 150.4 (C-2), 146.1, 141.9, 140.1, 135.5 (C-
6, C-4(triazole), Ar), 131.3, 130.9, 130.8, 130.6, 128.1, 127.7, 127.6,
124.8, 124.1, 124.0, 122.9, 122.3, 117.6, 117.2 (Ar, C-5(triazole)),
111.3, 111.2 (C-5), 86.4 (C-4¢), 84.8 (C-1¢), 78.8 (CAr3), 73.3 (C-3¢),
71.9 (C-5¢), 50.1 (C-6¢), 42.7 (CH2N), 40.9 (C-2¢), 25.6 (C(CH3)3),
17.7 (C(CH3)3), 12.9, 12.4 (CH3), -4.7, -4.8 (Si(CH3)2); HRMS-
ESI m/z 854.3324 [MNa]+: calcd (C44H49N7O8SiNa+) 854.3304.
Preparation of (1S,3R,4R,6R,7S)-1-(4,4¢-dimethoxytrityl-
oxymethyl)-7-hydroxy-3-(thymin-1-yl)-6-(4-(thymin-1-ylmethyl)-
1,2,3-triazol-1-yl)methyl-2,5-dioxabicyclo[2.2.1]heptane (18). To
a stirred solution of nucleoside 1727 (100 mg, 0.2 mmol) in a
mixture of anhydrous CH3CN and pyridine (1 : 1 v/v, 4 mL),
was added 4,4¢-dimethoxytrityl chloride (104 mg, 0.31 mmol).
The mixture was stirred at room temperature for 16 h and then
quenched by the addition of methanol (1 mL). The mixture
was concentrated under reduced pressure, and the residue was
dissolved in CH2Cl2 (40 mL). The organic phase was washed
with water (8 mL) and a saturated aqueous solution of NaHCO3
(8 mL). The organic phase was dried (MgSO4) and concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (3–5% EtOH in chloroform) to afford
the product 18 (97 mg, 60%) as a white solid; Rf 0.39 (10%
CH3OH in CH2Cl2); 1H NMR (300 MHz, CDCl3) d 10.30–10.10
(br m, 2H, NH), 8.00 (s, 1H, H-5(triazole)), 7.60 (s, 1H, H-6),
7.42–7.17 (m, 10H, Ar, H-6), 6.85–6.77 (m, 4H, Ar), 5.73 (s, 1H,
H-1¢), 4.82–4.47 (m, 7H, H-2¢, H-3¢, H-6¢, 2 ¥ CH2N), 3.74 (s, 6H,
2 ¥ OCH3), 3.55 (AB, 2H, J = 8.4, 10.2 Hz, H-5¢), 2.15 (br s, 1H,
OH), 1.75 (s, 3H, CH3), 1.59 (s, 3H, CH3); 13C NMR (CDCl3,
75 MHz) d 164.8, 164.5 (C-4), 158.8 (Ar), 151.4, 150.5 (C-2),
144.4, 142.2, 140.6 (C-6, C-4(triazole)), 135.3, 135.2, 134.6, 130.2,
128.2, 127.3 (Ar), 125.5 (C-5(triazole)), 113.5 (Ar), 111.2, 110.8
(C-5), 88.2, 87.2, 86.8, (CAr3, C-1¢, C-4¢), 79.8 (C-6¢), 79.1 (C-3¢),
72.1 (C-2¢), 58.4 (C-5¢), 55.4, 55.3 (OCH3), 51.0 (CH2N), 42.8
(CH2N), 12.6, 12.2 (CH3); HRMS-ESI m/z 814.2261 [MNa]+:
calcd (C42H43N7O10Na)+ 814.2807.
Preparation of 5¢-O-pixyl-5¢(S)-C-(4-(thymin-1-ylmethyl)-1,2,3-
triazol-1-yl)methylthymidine (14). A solution of compound 13
(450 mg, 0.54 mmol) dissolved in anhydrous THF (6 mL) was
added a 1.0 M solution of TBAF in THF (1 mL, 1.00 mmol) and
stirred at room temperature for 20 h. The mixture was poured into
ethyl acetate (40 mL) and the mixture was washed with a 10%
aqueous solution of NaHCO3 (40 mL). The aqueous phase was
extracted with ethyl acetate (3 ¥ 4 mL), and the combined organic
phases were dried (Na2SO4) and concentrated under reduced
pressure. The residue was purified by column chromatography
(10% MeOH and 0.2% pyridine in CH2Cl2) to afford the product
14 (353 mg, 91%) as a colorless foam; Rf 0.32 (10% MeOH in
1
CH2Cl2); H NMR (300 MHz, DMSO-d6) d 11.37 (s, H, NH),
11.30 (s, H, NH), 7.76–7.27 (m, 16H, H-6, H-5(triazole), Ar),
7.11–6.88 (m, 4H, Ar), 5.93 (t, 1H, J = 7.2 Hz, H-1¢), 5.00 (d,
1H, J = 4.5 Hz, OH-3¢), 4.83 (s, 2H, CH2N), 4.25 (dd, 1H, J =
9.3, 15.3 Hz, H-6¢), 3.77–3.69 (m, 2H, H-5¢, H-6¢), 3.49 (m, 1H,
H-3¢), 3.17 (1H, t, J = 2.7 Hz, H-4¢), 1.93–1.86 (m, 5H, H-2¢, CH3),
1.73 (s, 3H, CH3); 13C NMR (75 MHz, DMSO-d6) d 164.2, 163.7
(C-4), 151.0, 150.9, 150.6, 150.2, 147.2, 142.3, 140.9, 135.4 (Ar,
C-2, C-4(triazole), C-6), 130.9, 130.8, 130.3, 130.1, 127.8, 127.0,
124.2, 123.7, 123.6, 122.5, 122.0, 116.6, 116.2 (Ar, C-5(triazole)),
109.6, 108.8 (C-5), 85.0 (C-1¢), 83.6 (C-4¢), 77.1 (CAr3), 71.9 (C-
5¢), 70.0 (C-3¢), 49.6 (C-6¢), 42.0 (CH2N), 39.7 (C-2¢), 12.3, 11.9
(CH3); HRMS-ESI m/z 740.2437 [MNa]+: calcd (C38H35N7O8Na)+
740.2439.
Preparation
of
(1S,3R,4R,6R,7S)-7-(P-2-cyanoethoxy-
N,N - diisopropylaminophosphinyl)oxy - 1 - (4,4¢ - dimethoxytrityl) -
oxymethyl-3-(thymin-1-yl)-6-(4-(thymin-1-ylmethyl)-1,2,3-tri-
azol-1-yl)methyl-2,5-dioxabicyclo[2.2.1]heptane
(19). To
a
stirred solution of nucleoside 18 (58 mg, 0.073 mmol)
in anhydrous CH2Cl2 (1.0 mL) was added N,N-
diisopropylethylamine (55 mL, 0.31 mmol) and 2-cyanoethyl-
N,N-diisopropylphosphoramidochloridite (49 mL, 0.22 mmol),
and the mixture was stirred at room temperature for 112 h. The
mixture was diluted with CH2Cl2 (30 mL) and washed with a
saturated aqueous solution of NaHCO3 (5 mL), water (5 mL)
and brine (5 mL). The organic phase was dried (Na2SO4) and
concentrated under reduced pressure. The residue was purified by
column chromatography (30–50% acetone and 0.5% pyridine in
CH2Cl2) to give the product 19 (30 mg, 41%) as a white foam;
Rf 0.68 (10% CH3OH in CH2Cl2); 31P NMR (CDCl3, 300 MHz)
Preparation
of
3¢-O-(P-2-cyanoethoxy-N,N-diisopropyl-
aminophosphinyl)-5¢-O-pixyl-5¢(S)-C-(4-(thymin-1-ylmethyl)-1,
2,3-triazol-1-yl)methylthymidine (15). To a stirred solution of
This journal is
The Royal Society of Chemistry 2011
Org. Biomol. Chem., 2011, 9, 1381–1388 | 1387
©